Advertisement
New Zealand markets closed

  • NZX 50

    11,836.04
    -39.31 (-0.33%)
     

  • NZD/USD

    0.5928
    +0.0009 (+0.15%)
     

  • ALL ORDS

    7,898.90
    +37.90 (+0.48%)
     

  • OIL

    82.15
    -0.54 (-0.65%)
     

  • GOLD

    2,394.00
    +5.60 (+0.23%)
     

Terns Pharmaceuticals to Participate in Guggenheim Healthcare Talks 2023 Oncology Conference

Terns Pharmaceuticals, Inc.
·1-min read
Terns Pharmaceuticals, Inc.
Terns Pharmaceuticals, Inc.

FOSTER CITY, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today announced that management will participate in a fireside chat at the Guggenheim Healthcare Talks 2023 Oncology Conference on Thursday, February 9, 2023 at 10:10 a.m. ET.

A live audio webcast of the event will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com. A replay of the webcast will be archived on Terns’ website for 30 days following the event.

About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and NASH. Terns’ pipeline includes four clinical stage development programs including an allosteric BCR-ABL inhibitor, a THR-β agonist, an FXR agonist, a VAP-1 inhibitor, and preclinical small-molecule GLP-1 receptor agonist and GIPR modulator programs. For more information, please visit: www.ternspharma.com.

Contacts for Terns

Investors
Justin Ng
investors@ternspharma.com

Media
Jenna Urban
Berry & Company Public Relations
media@ternspharma.com